Thermo Fisher to sell microbiology business to PE firm Astorg for over $1 billion - Reuters

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPY0NwSmdCN3JITGNZUllySnRDZWtjRUhreGN1MXg3aDZTV19RRDBTY0hKaFd3QS02UkdJdUpqaFNLM2FyN1VhdjNldGxMRTdVT04tU1NFeWRMSEwtVWRtR0x2NmFWc0NWWGg5VElXWHpvcDU2RGdRRTZUYkktcEt1M0p3SEFwNWhrQThDaHB1SUhoSUNkZ1JIajcyN3NtOG9rNmZUdlZDcnpFQUIxZDR1NC1jVVhTbzNMRkYxc1lIOWF5eWM?oc=5" target="_blank">Thermo Fisher to sell microbiology business to PE firm Astorg for over $1 billion</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Thermo Fisher Scientific has agreed to sell its microbiology business to Astorg for approximately $1.08 billion, comprising cash and a $50 million seller note. The microbiology unit, part of Thermo Fisher's specialty diagnostics segment, generated $645 million in revenue in 2025. The transaction is expected to close in the second half of 2026 and may dilute adjusted earnings per share by $0.15 in the first full year after closing.

Thermo Fisher Scientific announced the sale of its microbiology business to private equity firm Astorg for $1.08 billion. The microbiology business supplies antimicrobial susceptibility testing and culture media products used for clinical, pharmaceutical, and food safety applications. The unit recorded $645 million in revenue in 2025. The transaction is expected to close in the second half of 2026 and may dilute adjusted earnings per share by $0.15 in the first full year after closing.

Thermo Fisher Scientific announced it will sell its microbiology business to private equity firm Astorg for about $1.08 billion. The deal includes cash and a $50 million seller note. The microbiology business supplies antimicrobial susceptibility testing and culture media products used for clinical, pharmaceutical, and food safety applications. The unit, part of Thermo Fisher's specialty diagnostics segment, recorded $645 million in revenue in 2025. The company expects the transaction to close in the second half of 2026 and anticipates a dilution of $0.15 to adjusted earnings per share in the first full year after closing.